Diabetes: Breaking news! Rosiglitazone and cardiovascular risk

Nature Reviews Cardiology

Volumn 7, Issue 12, 2010, Pages 670-672

  Kaul, Sanjay ^a   Diamond, George A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG FATALITY; EDEMA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; STROKE; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 78649417401     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.160     Document Type: Short Survey

References (10)

1. Nissen, S. E & Wolski, K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170, 1191-1201 (2010).
2. Graham, D. J. et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411-418 (2010).
3. McGuire, D. K. et al. Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function. Eur. Heart J. doi:10.1093/eurheartj/ehq228.
4. Nissen, S. E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007).
5. Diamond, G. A., Bax, L. & Kaul, S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann. Intern. Med. 147, 578-581 (2007).
6. FDA. FDA Briefing Document: Joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee July 30, 2007. FDA [onlinel. http://www.fda.aov/ohrms/ dockets/ac/07/briefing/2007-4308bl-02-fda-backgrounder.pdf (2007).
7. FDA. FDA adds boxed warning for heart-related risk to anti-diabetes drug Avandia. FDA [online], http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ucml09026.htm (2009).
8. Rucker, G. & Schumacher, M. Simpson's paradox visualized: the example of the rosiglitazone meta-analysis. BMC Med. Res. Methodol. 8. 34 (2008).
9. Friedrich, J. O., Adhikari, N. K. & Beyene, J. Inclusion of zero total event trials in metaanalyses maintains analytic consistency and incorporates all available data. BMC Med. Res. Methodol. 7, 5-11 (2007).
10. Dargie, H. J. et al. A randomized, placebocontrolled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J. Am. Coll. Cardiol. 49, 1696-1704 (2007).